tremelimumab
Novel First-Line Therapy’s OS Benefit for Liver Cancer Persists
Long-term overall survival in hepatocellular carcinoma with tremelimumab plus durvalumab treatment is durable, ...
OCTOBER 27, 2023
New Treatment for Unresectable Hepatocellular Carcinoma
The FDA has approved tremelimumab (Imjudo, AstraZeneca) in combination with durvalumab (Imfinzi, AstraZeneca) for ...
OCTOBER 31, 2022
Tremelimumab/Durvalumab Combo Promising for Unresectable HCC
Combining a single priming dose of tremelimumab and durvalumab significantly improved overall survival in the ...
FEBRUARY 11, 2022
Load more